BioSeed 2025 | OBN (UK) Ltd‌ on Glue Up

BioSeed, now in its ninth year, is taking place in London on Monday 20 January 2025 at etc. venues County Hall.

Owned and organised by OBN, BioSeed is a fast-paced, one-day pitching event where innovative early-stage life sciences companies seeking seed funding, showcase to and meet with an extensive audience of active life sciences investors.

Since our first BioSeed event in 2017, we've welcomed: 436 Seed Stage Companies, who've presented to over a combined audience of over 1100 active life sciences investors.

Key features of the 2025 event include:

Around 40 x 5-minute company presentations from early-stage life sciences R&D companies seeking seed stage funding
Private pre-scheduled partnering meetings in-person on 20 January, and virtually on 21 January (powered by PartneringONE)
Networking opportunities throughout the day, along with access to the post-event drinks reception
Inspirational keynote presentations

BioSeed attendance is exclusively for:

Early stage R&D companies seeking seed stage funding
Technology Transfer teams from academic institutions seeking funding for their spin out companies
Life sciences Investors looking for new funding opportunities
A limited number of corporate and industry sponsors

R&D Company Showcase Packages include:

A live and in-person 5-minute company showcase presentation
Pre-event presenter training and presentation content feedback service
Access to the private partnering meeting platform, in-person on 20 January, and virtually on 21 January
Extensive promotion of your company on social media, OBN marketing emails and the BioSeed website
Full day attendance along with the post-event networking reception

R&D Company Showcase Presentation Costs:

OBN Member: £500 + VAT
Non-Member: £600 + VAT
Additional tickets for colleagues of showcase presenters : £200 + VAT (subject to availability)

Investor Registration Details:

BioSeed Investor tickets are available on a complimentary basis, strictly for those actively seeking new investment opportunities in the life sciences sector. This includes VCs, Angel Investors, Family Offices, Private Equity and Big Pharma Venture Funds